AbbVie's immunology newbies Skyrizi and Rinvoq pick up the slack from declining Humira, but safety questions dog execs

AbbVie's immunology newbies Skyrizi and Rinvoq pick up the slack from declining Humira, but safety questions dog execs

Source: 
Fierce Pharma
snippet: 

When AbbVie won FDA approval for its next-generation immunology drugs Skyrizi and Rinvoq in 2019, the company had high hopes that the drugs could fill what threatened to be a gaping hole in the top line from the impending patent losses on the $20-billion-a-year Humira. Wall Street skeptics weren’t so sure.